326 related articles for article (PubMed ID: 35408980)
1. Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?
Papadakos SP; Dedes N; Pergaris A; Gazouli M; Theocharis S
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408980
[TBL] [Abstract][Full Text] [Related]
2. Emerging Evidence for the Clinical Relevance of Pancreatic Cancer Exosomes.
Massoumi RL; Hines OJ; Eibl G; King JC
Pancreas; 2019 Jan; 48(1):1-8. PubMed ID: 30531240
[TBL] [Abstract][Full Text] [Related]
3. CKAP4, a DKK1 Receptor, Is a Biomarker in Exosomes Derived from Pancreatic Cancer and a Molecular Target for Therapy.
Kimura H; Yamamoto H; Harada T; Fumoto K; Osugi Y; Sada R; Maehara N; Hikita H; Mori S; Eguchi H; Ikawa M; Takehara T; Kikuchi A
Clin Cancer Res; 2019 Mar; 25(6):1936-1947. PubMed ID: 30610103
[TBL] [Abstract][Full Text] [Related]
4. Exosomes and the Future of Immunotherapy in Pancreatic Cancer.
Batista IA; Melo SA
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699928
[TBL] [Abstract][Full Text] [Related]
5. A Current Synopsis of the Emerging Role of Extracellular Vesicles and Micro-RNAs in Pancreatic Cancer: A Forward-Looking Plan for Diagnosis and Treatment.
Trifylli EM; Kriebardis AG; Koustas E; Papadopoulos N; Fortis SP; Tzounakas VL; Anastasiadi AT; Sarantis P; Vasileiadi S; Tsagarakis A; Aloizos G; Manolakopoulos S; Deutsch M
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542378
[TBL] [Abstract][Full Text] [Related]
6. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Castillo J; Bernard V; San Lucas FA; Allenson K; Capello M; Kim DU; Gascoyne P; Mulu FC; Stephens BM; Huang J; Wang H; Momin AA; Jacamo RO; Katz M; Wolff R; Javle M; Varadhachary G; Wistuba II; Hanash S; Maitra A; Alvarez H
Ann Oncol; 2018 Jan; 29(1):223-229. PubMed ID: 29045505
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma.
Nakamura S; Sadakari Y; Ohtsuka T; Okayama T; Nakashima Y; Gotoh Y; Saeki K; Mori Y; Nakata K; Miyasaka Y; Onishi H; Oda Y; Goggins M; Nakamura M
Ann Surg Oncol; 2019 Jul; 26(7):2104-2111. PubMed ID: 30820789
[TBL] [Abstract][Full Text] [Related]
8. Exploring the potential of exosomes in diagnosis and drug delivery for pancreatic ductal adenocarcinoma.
Xu B; Chen Y; Peng M; Zheng JH; Zuo C
Int J Cancer; 2023 Jan; 152(2):110-122. PubMed ID: 35765844
[TBL] [Abstract][Full Text] [Related]
9. Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer.
Li Z; Yanfang W; Li J; Jiang P; Peng T; Chen K; Zhao X; Zhang Y; Zhen P; Zhu J; Li X
Cancer Lett; 2018 Sep; 432():237-250. PubMed ID: 29709702
[TBL] [Abstract][Full Text] [Related]
10. Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer.
Vahabi M; Comandatore A; Centra C; Blandino G; Morelli L; Giovannetti E
Semin Cancer Biol; 2023 Dec; 97():50-67. PubMed ID: 37956937
[TBL] [Abstract][Full Text] [Related]
11. Exosomes derived from human umbilical cord mesenchymal stromal cells deliver exogenous miR-145-5p to inhibit pancreatic ductal adenocarcinoma progression.
Ding Y; Cao F; Sun H; Wang Y; Liu S; Wu Y; Cui Q; Mei W; Li F
Cancer Lett; 2019 Feb; 442():351-361. PubMed ID: 30419348
[TBL] [Abstract][Full Text] [Related]
12. Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?
Liu DSK; Mato Prado M; Giovannetti E; Jiao LR; Krell J; Frampton AE
Expert Rev Mol Diagn; 2019 Jul; 19(7):553-558. PubMed ID: 31159604
[No Abstract] [Full Text] [Related]
13. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S
J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515
[TBL] [Abstract][Full Text] [Related]
14. Exosomal integrins and their influence on pancreatic cancer progression and metastasis.
Casari I; Howard JA; Robless EE; Falasca M
Cancer Lett; 2021 Jun; 507():124-134. PubMed ID: 33741423
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers in pancreatic ductal adenocarcinoma.
Gallego J; López C; Pazo-Cid R; López-Ríos F; Carrato A
Clin Transl Oncol; 2017 Dec; 19(12):1430-1437. PubMed ID: 28616721
[TBL] [Abstract][Full Text] [Related]
16. Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?
Krantz BA; O'Reilly EM
Clin Cancer Res; 2018 May; 24(10):2241-2250. PubMed ID: 29269376
[TBL] [Abstract][Full Text] [Related]
17. c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer.
Lux A; Kahlert C; Grützmann R; Pilarsky C
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284422
[TBL] [Abstract][Full Text] [Related]
18. Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis.
Li J; Li Z; Jiang P; Peng M; Zhang X; Chen K; Liu H; Bi H; Liu X; Li X
J Exp Clin Cancer Res; 2018 Jul; 37(1):177. PubMed ID: 30064461
[TBL] [Abstract][Full Text] [Related]
19. The need for effective pancreatic cancer detection and management: a biomarker-based strategy.
Crawley AS; O'Kennedy RJ
Expert Rev Mol Diagn; 2015; 15(10):1339-53. PubMed ID: 26394703
[TBL] [Abstract][Full Text] [Related]
20. Cancer-derived small extracellular vesicles: emerging biomarkers and therapies for pancreatic ductal adenocarcinoma diagnosis/prognosis and treatment.
Zhang W; Campbell DH; Walsh BJ; Packer NH; Liu D; Wang Y
J Nanobiotechnology; 2022 Oct; 20(1):446. PubMed ID: 36242076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
